RU2010152689A - Способы лечения с применением белков, связывающих рецептор интерлейкина-21 - Google Patents

Способы лечения с применением белков, связывающих рецептор интерлейкина-21 Download PDF

Info

Publication number
RU2010152689A
RU2010152689A RU2010152689/15A RU2010152689A RU2010152689A RU 2010152689 A RU2010152689 A RU 2010152689A RU 2010152689/15 A RU2010152689/15 A RU 2010152689/15A RU 2010152689 A RU2010152689 A RU 2010152689A RU 2010152689 A RU2010152689 A RU 2010152689A
Authority
RU
Russia
Prior art keywords
binding protein
binding fragment
individual
group
antigen
Prior art date
Application number
RU2010152689/15A
Other languages
English (en)
Russian (ru)
Inventor
Лэйрд БЛУМ (US)
Лэйрд БЛУМ
Давиндер ДЖИЛЛ (US)
Давиндер ДЖИЛЛ
Юлия ВУГМЕЙСТЕР (US)
Юлия ВУГМЕЙСТЕР
Дебора А. ЯНГ (US)
Дебора А. Янг
Маргот О'ТУЛ (US)
Маргот О'ТУЛ
Хит М. ГЬЮЭЙ (US)
Хит М. ГЬЮЭЙ
Карисса К. ЭДКИНС (US)
Карисса К. ЭДКИНС
Эми Арлин УИВЕР (US)
Эми Арлин УИВЕР
Садхана ДЖАИН (US)
Садхана ДЖАИН
Майя АРАИ (US)
Майя АРАИ
Original Assignee
УАЙТ ЭлЭлСи (US)
УАЙТ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by УАЙТ ЭлЭлСи (US), УАЙТ ЭлЭлСи filed Critical УАЙТ ЭлЭлСи (US)
Publication of RU2010152689A publication Critical patent/RU2010152689A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
RU2010152689/15A 2008-05-23 2009-05-26 Способы лечения с применением белков, связывающих рецептор интерлейкина-21 RU2010152689A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5554308P 2008-05-23 2008-05-23
US61/055,543 2008-05-23
US9947608P 2008-09-23 2008-09-23
US61/099,476 2008-09-23

Publications (1)

Publication Number Publication Date
RU2010152689A true RU2010152689A (ru) 2012-06-27

Family

ID=41092124

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010152689/15A RU2010152689A (ru) 2008-05-23 2009-05-26 Способы лечения с применением белков, связывающих рецептор интерлейкина-21

Country Status (13)

Country Link
US (2) US8178097B2 (cg-RX-API-DMAC7.html)
EP (1) EP2296689A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520989A (cg-RX-API-DMAC7.html)
KR (1) KR20110021919A (cg-RX-API-DMAC7.html)
CN (1) CN102149403A (cg-RX-API-DMAC7.html)
AR (1) AR072136A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009248812A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912998A2 (cg-RX-API-DMAC7.html)
CA (1) CA2725154A1 (cg-RX-API-DMAC7.html)
IL (1) IL209455A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010012812A (cg-RX-API-DMAC7.html)
RU (1) RU2010152689A (cg-RX-API-DMAC7.html)
WO (1) WO2009143526A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
KR20130011056A (ko) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
CN102532320A (zh) * 2012-03-06 2012-07-04 中国药科大学 全人源的抗人白介素21受体的单链抗体及其应用
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2019160978A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
KR102255964B1 (ko) * 2018-11-19 2021-05-24 한국생명공학연구원 신규한 il-15-il-21 융합 폴리펩티드 및 이의 용도
WO2021023108A1 (zh) * 2019-08-02 2021-02-11 正大天晴康方(上海)生物医药科技有限公司 一种抗pd-1抗体及其医药用途
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE60036930T2 (de) 1999-03-09 2008-10-09 Zymogenetics, Inc., Seattle Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
AU5142300A (en) 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
CA2420992C (en) * 2000-04-05 2010-07-13 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
JP2004500845A (ja) 2000-05-11 2004-01-15 ジェネティクス　インスティテュート，エルエルシー サイトカインレセプターファミリーのメンバーであるｍｕ−１
WO2003040313A2 (en) * 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP1531850B1 (en) * 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
JP4776228B2 (ja) * 2002-07-15 2011-09-21 ワイス・エルエルシー Ｔヘルパー（ｔｈ）細胞の発生および機能を調節するための方法および組成物
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
ZA200507235B (en) 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
AU2004275871A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
CA2566333A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
KR20070057789A (ko) * 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
BRPI0912998A2 (pt) 2015-10-13
IL209455A0 (en) 2011-01-31
US8178097B2 (en) 2012-05-15
CN102149403A (zh) 2011-08-10
AR072136A1 (es) 2010-08-11
US20090298081A1 (en) 2009-12-03
US20120276102A1 (en) 2012-11-01
AU2009248812A1 (en) 2009-11-26
MX2010012812A (es) 2011-01-21
EP2296689A1 (en) 2011-03-23
CA2725154A1 (en) 2009-11-26
JP2011520989A (ja) 2011-07-21
WO2009143526A1 (en) 2009-11-26
KR20110021919A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
RU2010152689A (ru) Способы лечения с применением белков, связывающих рецептор интерлейкина-21
Di Meglio et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans
Holla et al. Shared transcriptional profiles of atypical B cells suggest common drivers of expansion and function in malaria, HIV, and autoimmunity
Locci et al. Activin A programs the differentiation of human TFH cells
Corvaisier et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation
Lee et al. Regulating human Th17 cells via differential expression of IL-1 receptor
Nagafuchi et al. Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4+ T cells and disease activity
Hardt et al. Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis
Moghaddas et al. The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders
Cantarini et al. Immunometabolic biomarkers of inflammation in Behcet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens
Blum et al. Circulating plasmablasts are elevated and produce pathogenic anti‐endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension
Fineschi et al. Inflammation and interferon signatures in peripheral B-lymphocytes and sera of individuals with fibromyalgia
Chetaille Nézondet et al. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases
Ridgley et al. Il-6 mediated transcriptional programming of naïve CD4+ T cells in early rheumatoid arthritis drives dysregulated effector function
Vidal‐Pedrola et al. Characterization of age‐associated B cells in early drug‐naïve rheumatoid arthritis patients
Aira et al. Immunological evaluation of rheumatoid arthritis patients treated with itolizumab
KR102034757B1 (ko) Cd6 결합 파트너의 용도 및 이에 기초한 방법
Davies et al. Aberrant cell signalling in PBMCs upon IFN‐α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature
Du et al. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients
Jäger et al. IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis
Lu et al. Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease
EP3440461A1 (en) Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
Byng-Maddick et al. Tumor necrosis factor (TNF) bioactivity at the site of an acute cell-mediated immune response is preserved in rheumatoid arthritis patients responding to anti-TNF therapy
Wines et al. Distinctive expression of interleukin‐23 receptor subunits on human Th17 and γδ T cells
Filippini et al. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140506